Colon Cancer

Gene-Based Clinical Trial Initiated

Published in Gene Therapy Weekly, May 20th, 1996

GenVec, Rockville, Maryland, has initiated a clinical study of a new gene-based treatment Ad(GV)CD.10, for liver metastases of colorectal cancer, one of the leading causes of cancer deaths in the U.S.

The announcement was made by Thomas D'Alonzo, President and CEO of the company. The first phase of the Ad(GV)CD.10 trial will seek to evaluate the product's safety and anti-tumor effects.

GenVec is a developer of in vivo gene-based therapies and gene delivery systems for the treatment of acute and chronic diseases. In vivo genetic therapy permits the administration of corrective or therapeutic genes directly into affected tissues.

...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (1996-05-20)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry